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ABSTRACT
Introduction: The impact of psoriasis varies
with the body region affected. In addition,
patients have different perceptions of disease
improvement and treatment satisfaction based
on the location of skin clearance with
treatment. The monoclonal antibody
secukinumab selectively targets
interleukin-17A—a central cytokine of
psoriasis—and provides rapid and sustained
clearance for moderate-to-severe psoriasis
affecting all body regions. The objective of this
study was to evaluate the efficacy of
secukinumab on moderate-to-severe psoriasis
affecting the trunk, upper limbs, and lower
limbs.
Methods: Data were pooled from four phase 3
studies. To be included in the analysis for each
body region, patients were required to have a
Psoriasis Area and Severity Index (PASI) score
C12 for that body region and psoriasis covering
C10% of the surface area of that region.
Secukinumab was administered at Baseline,
Weeks 1, 2 and 3, and then every 4 weeks
from Week 4 to 48.
Results: Across the trunk, upper limbs, and lower
limbs, initial PASI subscore responses were
sustained to Week 52. At Week 52, trunk
(T) PASI 90\100 responses were achieved by
78.4%\71.1% of patients receiving secukinumab
300 mg, respectively, and by 66.3%\56.9% of
patients receiving secukinumab 150 mg,
respectively. At Week 52, upper limb (UL) PASI
90\100 responses were achieved by 67.3%\59.1%
of patients receiving secukinumab 300 mg,
respectively, and by 50.3%\43.3% of patients
receiving secukinumab 150 mg, respectively. At
Week 52, lower limb (LL) PASI 90\100 responses
were achieved by 63.9%\55.3% of patients
receiving secukinumab 300 mg, respectively,
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and by 45.1%\36.4% of patients receiving
secukinumab 150 mg, respectively. A 50%
reduction in mean PASI subscore occurred after
2.8, 2.9, and 3.4 weeks with secukinumab 300 mg
on the trunk, upper limbs, and lower limbs,
respectively.
Conclusion: Secukinumab provided robust and
sustained efficacy for moderate-to-severe
psoriasis affecting the trunk, upper limbs, and
lower limbs.
Funding: Novartis Pharmaceuticals Corporation.
Trial registration: ClinicalTrials.gov identifiers:
NCT01365455, NCT01358578, NCT01555125,
and NCT01636687.
Keywords: Lower limbs; Moderate-to-severe
psoriasis; Phase 3; Plaque psoriasis; Pooled
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INTRODUCTION
Secukinumab, a human monoclonal antibody
that selectively binds to and neutralizes
interleukin-17A, is approved for the treatment
of moderate-to-severe plaque psoriasis in the
United States and Europe. In phase 3 studies,
the efficacy of secukinumab has been
demonstrated based on significant
improvements in Psoriasis Area and Severity
Index (PASI) responses compared with placebo,
etanercept, and ustekinumab [1–4].
Although PASI is infrequently used in
clinical practice, an improvement from
Baseline of at least 75% (PASI 75) is well
established in clinical trials as a clinically
meaningful reduction in disease severity that
also correlates with improvements in patients’
quality of life [5]. As PASI includes separate
assessments for psoriasis signs (erythema,
thickening, and scaling) on the head and
neck, trunk (including the genitals), upper
limbs, and lower limbs [5], PASI results can be
adequately used to assess the effects of
treatment on specific body regions. It is
important to evaluate improvements in
psoriasis on different body regions as psoriasis,
on certain areas, disproportionately impacts
quality of life [6, 7]. Accordingly, patients’
perceived improvement and satisfaction with
treatment may be differently impacted based on
the areas where improvement occurs.
In this issue of Dermatology and Therapy,
Kircik et al. reported the robust and sustained
clearance of psoriatic lesions on the head and
neck following treatment with secukinumab
300 mg and secukinumab 150 mg in a pooled
population from four phase 3 trials [8]. Here we
present the efficacy of secukinumab (300 or
150 mg), on the trunk, upper limbs, and lower
limbs from the same pooled population, using
PASI 90 and PASI 100 response rates. These
levels of improvement have become the new
benchmarks for success in treating patients with
moderate-to-severe psoriasis, especially with
new biologic agents [9].
METHODS
Study Design
Pooled data to Week 52 from four phase 3,
randomized, placebo-controlled, double-blind
studies [Efficacy of Response and Safety of
Two Fixed Secukinumab Regimens in Psoriasis
(ERASURE, ClinicalTrials.gov identifier:
NCT01365455), Full Year Investigative
Examination of Secukinumab vs. Etanercept
Using Two Dosing Regimens to Determine
Efficacy in Psoriasis (FIXTURE, ClinicalTrials.gov
identifier: NCT01358578), First Study of
Secukinumab in Pre-filled Syringes in Subjects
With Chronic Plaque-type Psoriasis (FEATURE,
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ClinicalTrials.gov identifier: NCT01555125), and
Judging the Efficacy of Secukinumab in Patients
With Psoriasis Using Autoinjector: A Clinical Trial
Evaluation Treatment Results (JUNCTURE,
ClinicalTrials.gov identifier: NCT01636687)]
of secukinumab in patients with
moderate-to-severe plaque psoriasis were used
for this analysis. A detailed description of the
design for these trials can be found elsewhere
[1–3]. Briefly, subjects received secukinumab (300
or 150 mg) at Baseline, Weeks 1, 2 and 3, and
then every 4 weeks from Week 4 to 48. At Week
12, patients receiving placebo were randomized
to secukinumab.
Study Population
All studies included adults 18 years of age or
older with a diagnosis of moderate-to-severe
plaque psoriasis of at least 6 months prior to
randomization that was poorly controlled with
topical, phototherapy, and\or systemic
therapy. To meet the definition of
moderate-to-severe psoriasis, patients were
required to have a composite PASI score C12,
an Investigator’s Global Assessment modified
2011 (IGA mod 2011) [10] score C3, and total
affected body surface area C10% at Baseline. To
be included in the subanalysis for a given body
region, patients were required to have a PASI
score C12 for that specific body region and
psoriasis covering C10% of the surface area of
that region. Exclusion criteria included active,
ongoing inflammatory diseases; active,
ongoing, chronic or recurrent infectious
disease, or evidence of tuberculosis infection;
or an underlying condition significantly
immunocompromising the patient and\or
placing the patient at unacceptable risk for
receiving an immunomodulatory therapy (e.g.,
lymphoproliferative disease, malignancy,
history of malignancy within the past 5 years;
and\or past medical history of human
immunodeficiency virus, hepatitis B, or
hepatitis C).
Efficacy Assessments
In all 4 trials, the coprimary efficacy variables
were PASI 75 response rates and IGA mod 2011
0\1 response rates at Week 12. The proportion
of patients achieving PASI 90 at Week 12 was a
key secondary endpoint in all trials.
Statistical Analysis
Efficacy data from the ERASURE, FIXTURE,
FEATURE, and JUNCTURE trials were pooled
through Week 52. Missing values were imputed
by multiple imputation (MI). The SAS (version
9.3, SAS Institute, Cary, NC, USA) MI procedure
was used to generate data sets for 500
imputations. The MI method was used in this
study because it more accurately reflects real
world response rates than the non-responder
imputation method, which underestimates
PASI responses [11]. This article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Patient Demographics
Of the 2403 randomized patients, the number
eligible for the evaluation of each body region
(PASI score C12 for that specific body region
and psoriasis covering C10% of the surface area
of that region) who received secukinumab were
1092 for the trunk, 1233 for the upper limbs,
and 1309 for the lower limbs. As reported by
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Kircik et al. [8], demographic characteristics for
the pooled population were well balanced
across secukinumab treatment groups [8].
Briefly, approximately 70% of patients were
male and White and mean PASI scores at
randomization were approximately 23.
Efficacy
At Week 12 and Week 52, PASI 75 subscore
responses on the trunk, upper limbs, and lower
limbs were high for patients receiving both
secukinumab 300 mg and secukinumab 150 mg.
PASI 75 subscore response rates at Week 12 were
well maintained up to Week 52. The most
robust efficacy was observed on the trunk,
followed by the upper limbs and then the
lower limbs (Table 1).
PASI 90 and PASI 100 subscore response rates
to Week 52 for each body region are shown in
Figs. 1 and 2, respectively. For all body regions,
initial PASI 90 and PASI 100 subscore responses
were maintained to Week 52. At Week 16, a
numerically greater proportion of patients
achieved skin clearance on the trunk than on
the upper limbs or the lower limbs. Trunk
(T) PASI 90 and TPASI 100 responses were
achieved by 82.5% and 70.0% of patients
receiving secukinumab 300 mg, respectively,
and by 70.8% and 58.9% of patients receiving
secukinumab 150 mg, respectively. Upper limb
(UL) PASI 90 and ULPASI 100 responses were
achieved by 72.1% and 61.4% of patients
receiving secukinumab 300 mg, respectively,
and by 57.6% and 43.7% of patients receiving
secukinumab 150 mg, respectively. Lower limb
(LL) PASI 90 and LLPASI 100 responses were
achieved by 68.9% and 52.9% of patients
receiving secukinumab 300 mg, respectively,
and by 50.5% and 35.8% of patients receiving
secukinumab 150 mg, respectively.
The trend for a greater response to
secukinumab on the trunk than on the upper
limbs or the lower limbs was maintained up to
Week 52. At Week 52, TPASI 90 and TPASI 100
responses were achieved by 78.4% and 71.1% of
patients receiving secukinumab 300 mg,
respectively, and by 66.3% and 56.9% of
patients receiving secukinumab 150 mg,
respectively. ULPASI 90 and ULPASI 100
Table 1 Percentage of patients who achieved PASI 75 at Week 12 and Week 52 by body region
Parameter Secukinumab 300 mg Secukinumab 150 mg
Week 12
TPASI 75 88.8% (488/550) 78.0% (423/542)
ULPASI 75 83.5% (510/611) 72.9% (454/622)
LLPASI 75 81.2% (530/652) 66.1% (434/657)
Week 52
TPASI 75 90.9% (500/550) 82.1% (445/542)
ULPASI 75 85.9% (525/611) 71.6% (445/622)
LLPASI 75 82.1% (535/652) 66.3% (436/657)
Missing values were imputed by multiple imputation
LLPASI lower limb Psoriasis Area and Severity Index, TPASI trunk Psoriasis Area and Severity Index, ULPASI upper limb
Psoriasis Area and Severity Index
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responses were achieved by 67.3% and 59.1% of
patients receiving secukinumab 300 mg,
respectively, and by 50.3% and 43.3% of
patients receiving secukinumab 150 mg,
respectively. LLPASI 90 and LLPASI 100
responses were achieved by 63.9% and 55.3%
of patients receiving secukinumab 300 mg,
respectively, and by 45.1% and 36.4% of
patients receiving secukinumab 150 mg,
respectively.
As shown in Fig. 3, treatment with
secukinumab rapidly improved plaque
psoriasis, with a 50% reduction in mean PASI
subscore with secukinumab 300 mg observed
after 2.8 weeks [95% confidence interval (CI)
2.6–2.9] on the trunk, 2.9 weeks (95% CI
2.8–3.1) on the upper limbs, and 3.4 weeks
(95% CI 3.2–3.6) on the lower limbs. With
administration of secukinumab 150 mg, a 50%
reduction in mean PASI subscore was observed
after 3.4 weeks (95% CI 3.2–3.6) on the trunk,
3.7 weeks (95% CI 3.5–3.9) on the upper limbs,
and 4.5 weeks (95% CI 4.1–4.9) on the lower
limbs.
DISCUSSION
Results of this pooled analysis show that
secukinumab provides rapid and sustained
efficacy over 52 weeks in treating patients with
moderate-to-severe plaque psoriasis on the
trunk, upper limbs, and lower limbs. These
findings are consistent with the efficacy of
secukinumab observed for psoriasis lesions
affecting the head and neck [8], indicating that
secukinumab is effective for treating psoriasis
Fig. 1 PASI 90 subscore response rates by body region.
Missing values were imputed by multiple imputation.
Clinical response rates for a trunk, b upper limbs, and
c lower limbs from Baseline to Week 52. n Represents the
number of evaluable subjects. PASI 90 90% improvement
from Baseline Psoriasis Area and Severity Index
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regardless of the body region affected. The most
robust PASI 90\100 subscore responses at Week
52 with secukinumab 300 mg occurred on the
trunk (78.4%\71.1%) and the head and neck
(76.0%\68.7%) [8] region. Additionally, a large
proportion of patients also achieved PASI 90\100
subscore responses with secukinumab 300 mg on
the upper limbs (67.3%\59.1%) and the lower
limbs (63.9%\55.3%) at Week 52. A similar trend
was observed with secukinumab 150 mg at Week
52 between the trunk (66.3%\56.9%), head and
neck (61.4%\53.1%) [8], upper limbs
(50.3%\43.3%), and lower limbs (45.1%\36.4%).
More rapid responses were observed with
the treatment of secukinumab 300 mg
compared with secukinumab 150 mg across
all body regions. The time to a 50% mean
reduction in PASI subscore was quickest with
secukinumab 300 mg for the head and neck
region (2.0 weeks) [8], followed by the trunk
(2.8 weeks), upper limbs (2.9 weeks), and
lower limbs (3.4 weeks). A similar trend was
reported for secukinumab 150 mg, with the
time to a 50% mean reduction in PASI
subscore occurring first in the head and neck
region (2.7 weeks) [8] followed by the trunk
(3.4 weeks), upper limbs (3.7 weeks), and
lower limbs (4.5 weeks). Additionally, in
ERASURE and FIXTURE, improvement in
PASI scores were mirrored by significant
improvements in patient-reported symptoms
of itching, pain, and scaling compared with
placebo up to Week 12 as recorded by the
Psoriasis Symptom Diary [12]. A limitation
of this study is the lack of a control group
after Week 12.
Fig. 2 PASI 100 subscore response rates by body region.
Missing values were imputed by multiple imputation.
Clinical response rates for a trunk, b upper limbs, and
c lower limbs from Baseline to Week 52. n Represents the
number of evaluable subjects. PASI 100 100% improve-
ment from Baseline Psoriasis Area and Severity Index
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Safety findings for the pooled population
used in this analysis are reported separately by
Kircik et al. [8]. Briefly, adverse events were
observed at a similar rate between both
secukinumab doses, and the most common
adverse events through Week 52 were
nasopharyngitis and headache.
Findings from this study are consistent with
results from other studies that evaluated
treatment efficacy by body region. In these
studies, as well as in clinical practice, it has been
observed that biologic treatment response
typically starts on the head and upper body
and progresses downward to lower body regions
and extremities [13, 14]. For example, after
16 weeks of treatment with the tumor necrosis
factor-alpha inhibitor adalimumab, the greatest
PASI 100 subscore response rates were reported
on the head and neck (55.7%) and the trunk
(49.1%) compared with the upper limbs (33.3%)
and the lower limbs (30.6%) [14].
CONCLUSION
In conclusion, the results of our pooled analysis
demonstrated that, on the trunk, upper limbs,
and lower limbs, secukinumab—especially
300 mg—provided PASI 75, PASI 90, and PASI
100 subscore improvements that were rapid and
sustained. Disease clearance occurred rapidly on
highly visible areas of the skin, which is likely to
produce a significant emotional improvement
for patients. This study, and the accompanying
article by Kircik et al. [8], demonstrate the
Fig. 3 Percent change in mean PASI subscore over time by
body region. A repeated-measures, mixed-effects model was
used to analyze the mean percent change from Baseline for
a TPASI, b ULPASI, and c LLPASI subscores. The median
time to a 50% reduction in mean PASI subscore was
estimated from parametric bootstrap samples with the use of
linear interpolation between time points. CI conﬁdence
interval, LLPASI lower limb Psoriasis Area and Severity
Index, TPASI trunk Psoriasis Area and Severity Index,
ULPASI upper limb Psoriasis Area and Severity Index
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strong efficacy of secukinumab on different
body regions. Overall, these results indicate
that clear or almost clear skin (PASI 100 or
PASI 90) are appropriate treatment goals for
patients with moderate-to-severe plaque
psoriasis who are treated with secukinumab.
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